Industry insiders hope a new rule on breakthrough devices from the Centers for Medicare and Medicaid Services is a first step to expanding coverage for all new devices. While praising the proposal, Scott Gottlieb, former commissioner of the US Food and Drug Administration, said he doesn’t believe that will happen without a complete rethink of reimbursement pathways at the CMS.
“I’d be surprised if they extended [the reimbursement rule] to all devices,” Gottlieb said in an interview with Medtech Insight....
